Sugi Predict

Sugi Predict / Compounds / SCHEMBL1245514

SCHEMBL1245514

SCHEMBL1245514

N#Cc1ccc2nc(Cl)[nH]c2c1

nearest known ligand 0.58

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ PIN1 Q13526 1/20 0.58
▸ PKN1 Q16512 1/20 0.56
▸ PKN2 Q16513 1/20 0.56
▸ CSNK1D P48730 7/20 0.54
▸ CSNK1A1 P48729 5/20 0.54
▸ CSNK1G2 P78368 5/20 0.54
▸ GSK3B P49841 4/20 0.54
▸ METAP2 P50579 1/20 0.52
▸ METAP1 P53582 1/20 0.52
▸ PSMB8 P28062 1/20 0.51
▸ CHEK2 O96017 1/20 0.49
▸ RHEB Q15382 1/20 0.49
▸ GRIN1 Q05586 1/20 0.46
▸ GRIN2B Q13224 1/20 0.46
▸ DGAT1 O75907 1/20 0.43
▸ SOAT1 P35610 1/20 0.43
▸ KCNH2 Q12809 1/20 0.43
▸ CFB P00751 3/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1245512 0.86 RHEB (0.49) PIN1PKN1PKN2CSNK1DCSNK1A1
SCHEMBL2712166 0.79 PIN1 (0.62) PIN1PKN1PKN2CSNK1DCSNK1A1
SCHEMBL22219469 0.79 PIN1 (0.58) PIN1PKN1PKN2CSNK1DCSNK1A1
SCHEMBL12430878 0.79 CSNK1D (0.61) PIN1PKN1PKN2CSNK1DCSNK1A1
SCHEMBL1793328 0.79 PIN1 (0.58) PIN1PKN1PKN2CSNK1DCSNK1A1
SCHEMBL29439000 0.79 CSNK1D (0.61) PIN1PKN1PKN2CSNK1DCSNK1A1
SCHEMBL7792028 0.79 PIN1 (0.58) PIN1PKN1PKN2CSNK1DCSNK1A1
SCHEMBL7381841 0.78 GRIN1 (0.55) PIN1PKN1PKN2CSNK1DCSNK1A1
SCHEMBL21822330 0.78 PIN1 (0.54) PIN1PKN1PKN2CSNK1DCSNK1A1
SCHEMBL3341423 0.78 PKN1 (0.72) PKN1PKN2CSNK1DCSNK1A1CSNK1G2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3697410-B1 BENZIMIDAZOLE DERIVATIVES AND THEIR USES TEIJIN PHARMA LTD (JP) 2024-12-18 — — EP disclosed
CN-111417394-B Benzimidazole derivatives and uses thereof 帝人制药株式会社 2023-11-07 — — CN disclosed
EP-3397629-B1 METALLOENZYME INHIBITOR COMPOUNDS NQP 1598 LTD (KY) 2023-04-19 — — EP disclosed
EP-3397629-B1 METALLOENZYME INHIBITOR COMPOUNDS NQP 1598 LTD (KY) 2023-04-19 — — EP disclosed
US-11332459-B2 Benzimidazole derivatives and their uses TEIJIN PHARMA LIMITED (JP) 2022-05-17 — — US disclosed
US-11332459-B2 Benzimidazole derivatives and their uses TEIJIN PHARMA LIMITED (JP) 2022-05-17 — — US disclosed
CN-108779094-B Metalloenzyme inhibitor compounds NQP 1598公司 2021-11-16 — — CN disclosed
US-20200308145-A1 BENZIMIDAZOLE DERIVATIVES AND THEIR USES AMGEN INC. (US) 2020-10-01 — — US disclosed
US-20200308145-A1 BENZIMIDAZOLE DERIVATIVES AND THEIR USES AMGEN INC. (US) 2020-10-01 — — US disclosed
EP-3697410-A1 BENZIMIDAZOLE DERIVATIVES AND THEIR USES Amgen Inc. (US) 2020-08-26 — — EP disclosed
US-7074794-B2 Proline derivatives and the use thereof as drugs MITSUBISHI PHARMA CORPORATION (JP) 2006-07-11 — — US disclosed
US-7060722-B2 Proline derivatives and use thereof as drugs MITSUBISHI PHARMA CORPORATION (JP) 2006-06-13 — — US disclosed
EP-1633722-A2 PREPARATION AND USE OF ARYL ALKYL ACID DERIVATIVES FOR THE TREATMENT OF OBESITY Bayer Pharmaceuticals Corporation (US) 2006-03-15 — — EP disclosed
US-20050245538-A1 Proline derivatives and use thereof as drugs KITAJIMA HIROSHI 2005-11-03 — — US disclosed
CN-1186322-C Proline derivatives and use thereof as drugs MITSUBISHI PHARMACEUTICAL CO L (JP) 2005-01-26 — — CN disclosed
WO-2004100881-A2 PREPARATION AND USE OF ARYL ALKYL ACID DERIVATIVES FOR THE TREATMENT OF OBESITY BAYER PHARMACEUTICALS CORPORATION (US) 2004-11-25 — — WO disclosed
US-20040224997-A1 Preparation and use of aryl alkyl acid derivatives for the treatment of obesity BAYER PHARMACEUTICALS CORPORATION 2004-11-11 — — US disclosed
US-20040106655-A1 Proline derivatives and the use thereof as drugs MITSUBISHI TANABE PHARMA CORPORATION (JP) 2004-06-03 — — US disclosed
CN-1441779-A Proline derivatives and use thereof as drugs MITSUBISHI PHARMACEUTICAL CO L (JP) 2003-09-10 — — CN disclosed
EP-1308439-A1 PROLINE DERIVATIVES AND USE THEREOF AS DRUGS WELFIDE CORPORATION (JP) 2003-05-07 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040224997-A1 Preparation and use of aryl alkyl acid derivatives for the treatment of obesity FABP4, GPR119, LIPC PIN1 4035/4885PKN1 4611/4885PKN2 4517/4885
US-20050245538-A1 Proline derivatives and use thereof as drugs DPP4, DPP3, DPP7 PIN1 19/4885PKN1 2632/4885PKN2 2989/4885
US-20200308145-A1 BENZIMIDAZOLE DERIVATIVES AND THEIR USES TRPC6, TRPV6, TRPM6 PIN1 1258/4885PKN1 1322/4885PKN2 1016/4885
US-20040106655-A1 Proline derivatives and the use thereof as drugs DPP4, DPP3, DPP7 PIN1 20/4885PKN1 2057/4885PKN2 2958/4885
US-11332459-B2 Benzimidazole derivatives and their uses TRPC6, TRPV6, TRPM6 PIN1 1258/4885PKN1 1322/4885PKN2 1016/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.